Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Mon, 26 Oct 2026 05:05:21 -0400Copyright Q4 Inc. All rights reserved.UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease439368a1-32ba-405d-9f3a-151e462276a8https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspxTue, 20 Oct 2026 08:00:00 -0400Teva to Host R&D Day on Wednesday, November 11 in New York City12df8b0d-a2d1-4ae3-a478-10969058c429https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Host-RD-Day-on-Wednesday-November-11-in-New-York-City/default.aspxMon, 12 Oct 2026 17:45:00 -0400Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia143141f6-1a3d-420f-b3cf-49be317d1382https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Announces-U-S--Food-and-Drug-Administration-FDA-Approval-of-WELTRUZA-Olanzapine-For-Extended-Release-Injectable-Suspension-as-the-First-and-Only-Once-Monthly-Subcutaneous-Injectable-Olanzapine-for-Adults-with-Schizophrenia/default.aspxFri, 09 Oct 2026 07:00:00 -0400Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome8c950dfd-abf5-423f-8416-00d7aebdba41https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Presents-New-Efficacy-and-Safety-Data-with-Ecopipam-an-Investigational-Treatment-for-Pediatric-Patients-with-Tourette-Syndrome/default.aspxFri, 02 Oct 2026 08:00:00 -0400Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients9ac8290c-1745-4055-9697-bb12f85d1784https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Journal-of-Child-Neurology-Publishes-Review-Highlighting-Dopamines-Role-in-Tourette-Syndrome-and-Ecopipams-Selective-D1-Receptor-Mechanism-for-Tourette-Syndrome-in-Pediatric-Patients/default.aspxFri, 02 Oct 2026 08:00:00 -0400Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates51368328-af7e-4955-a4da-d3b0a3adb850https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Samsung-Bioepis-and-Teva-Expand-Strategic-Partnership-to-Advance-Up-to-Six-Potential-Biosimilar-Candidates/default.aspxThu, 01 Oct 2026 04:30:00 -0400TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness16b543be-4960-4c8e-91f2-12b7e7f21529https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/TAPI-Technology--API-Services-Names-Serge-Rogasik-CEO-to-lead-next-chapter-of-growth-and-competitiveness/default.aspxWed, 30 Sep 2026 16:32:00 -0400Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)f9d7fb5d-364e-4cd4-b7bc-2c55b7206cc2https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Continues-Biosimilar-Momentum-with-U-S--FDA-Approval-of-DEGEVMA-denosumab-adet-a-Biosimilar-to-Xgeva-denosumab/default.aspxMon, 28 Sep 2026 16:00:00 -0400Teva Releases Q3 2026 Aide Memoire392d5951-8ff6-4c7c-9ddb-1f6834fc7017https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Releases-Q3-2026-Aide-Memoire/default.aspxWed, 23 Sep 2026 16:45:00 -0400Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ETee5d60a9-5124-4c94-897a-674fef22b102https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Host-Conference-Call-to-Discuss-Third-Quarter-2026-Financial-Results-on-November-3-2026-at-8-a-m--ET/default.aspxWed, 23 Sep 2026 16:45:00 -0400